サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：抗生物質耐性の世界市場：疾患タイプ別、病原体タイプ別、薬剤クラス別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測
市場調査レポート
商品コード
1358223

抗生物質耐性の世界市場：疾患タイプ別、病原体タイプ別、薬剤クラス別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測

Antibiotic Resistance Market, By Disease Type, By Pathogen Type, By Drug Class, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 299 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗生物質耐性の世界市場：疾患タイプ別、病原体タイプ別、薬剤クラス別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測
出版日: 2023年09月01日
発行: AnalystView Market Insights
ページ情報: 英文 299 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗生物質耐性の市場規模は、2022年は80億570万米ドルとなり、2023年から2030年にかけてCAGR 6.1％で拡大すると予想されています。

抗生物質耐性市場 - 市場力学

  • 細菌感染症の有病率の増加が市場成長を拡大。
  • 従来の抗生物質に耐性を持つ細菌性疾患の蔓延が進むことで、新規治療薬への需要が高まり、市場成長が促進される可能性があります。抗生物質耐性が広がるにつれ、新たな抗生物質の必要性はより切迫したものとなります。このため、製薬企業による研究開発への投資が増加する可能性があります。細菌感染症の負担に関する世界の包括的推計が発表されています。2019年には、世界中で770万人が細菌感染に関連して死亡していることが判明しました。これは全世界の死亡者数の8人に1人に相当します。薬剤研究におけるAIと機械学習の統合は、新規抗生物質の創出を加速させる成長機会となります。しかし、抗生物質耐性は一般の人々やヘルスケアプロバイダーにさえ広く認識されていないです。そのため、誤った処方や乱用につながる可能性があります。

抗生物質耐性市場 - セグメンテーション分析

  • 世界の抗生物質耐性市場は、疾患タイプ、病原体タイプ、薬剤クラス別、エンドユーザー別、地域別にセグメント化されています。
  • 市場は疾患タイプに基づいて尿路感染症、腹腔内感染症、血流感染症、クロストリジウム・ディフィシル感染症、その他の4つのカテゴリーに分けられます。尿路感染症が市場成長を支配しています。尿路結石は、ヒト、特に女性が罹患する最も一般的な細菌性疾患の1つです。尿路結石は抗生物質で治療されることが多いです。しかし、抗生物質耐性の普及に伴い、尿路結石の管理と治療はより困難になっています。
  • 市場は、病原体タイプに基づいてアシネトバクター・バウマニ、緑膿菌、黄色ブドウ球菌、肺炎球菌、その他の4つのカテゴリーに分類される。アシネトバクター・バウマンニが市場の成長を支配しています。アシネトバクター・バウマンニには、急速に耐性メカニズムを獲得する固有の傾向があり、病院環境、特に集中治療室（ICU）において最も厄介な感染症の1つとなっています。
  • 市場は薬剤クラス別にオキサゾリジノン系、リポグリコペプチド系、テトラサイクリン系、その他の3つのカテゴリーに分類される。オキサゾリジノン系が市場を独占しており、予測期間中もその優位性を維持するとみられます。オキサゾリジノン系は、細菌感染症、特にグラム陽性病原体による感染症の治療に使用される抗生物質です。オキサゾリジノン系ではリネゾリドが最も有名です。メチシリン耐性黄色ブドウ球菌（MRSA）やバンコマイシン耐性腸球菌（VRE）などの多剤耐性病原体にも有効であることが示されており、特に重要な薬剤です。
  • 市場はエンドユーザー別に病院、在宅医療、専門クリニック、その他に分類されます。市場を独占しているのは病院部門です。病院は抗生物質耐性の発達に不可欠です。病院は耐性菌の温床であると同時に、こうしたスーパーバグに罹患した人々を治療する主戦場でもあります。病院が抗生物質耐性の発達に直面する意味は複雑であり、ヘルスケア市場に多大な影響を及ぼします。

抗生物質耐性市場 - 地理的洞察

地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。北米は、感染症の流行とヘルスケア支出の増加により、市場の成長を支配すると予想されています。北米、特に米国では多くの感染症が発生しており、その中には抗生物質耐性のものもあります。例えばMRSA（メチシリン耐性黄色ブドウ球菌）は、米国の多くの病院やヘルスケア現場で大きな問題となっています。米国は世界のどの国よりも、国民一人当たりのヘルスケア支出額が多いです。米国医師会によれば、その収入の大部分は研究、医薬品開発、診断に費やされています。米国の医療費は2021年に2.7％増の4兆3,000億米ドル、国民1人当たり1万2,914米ドルとなっています。この成長率は2020年（10.3％）より大幅に低いです。欧州とアジア太平洋地域は、効果的な抗生物質治療に対する需要の高まりから、二重特異性耐性市場の需要が増加すると予測されます。

抗生物質耐性市場 - 競合情勢

抗生物質耐性は、世界の主要課題として浮上しています。細菌が進化して既存の薬に耐性を持つようになると、感染症の治療がより困難になり、病気の長期化、入院の増加、死亡率の上昇につながります。各製薬メーカーは抗生物質研究に積極的であったが、経済的圧力のため、一部の大手製薬会社は抗生物質研究プロジェクトを縮小または中止しています。Pfizer、Merck、GlaxoSmithKline、Rocheは製薬業界に携わる企業の代表格です。包括的な競合調査は、製薬企業、診断会社、研究機関、代替治療法を考慮しなければならないです。例えば、2021年5月、Basilea Pharmaceutical Ltd. (SIX: BSLN) は、薬剤耐性感染症の診断・予防・治療のための抗菌製品の早期開発を支援する世界・パートナーシップであるCARB-X（Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator）から、最大270万米ドルの助成金を獲得したと発表しました。

目次

第1章 抗生物質耐性市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 抗生物質耐性の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 抗生物質耐性産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 抗生物質耐性市場：COVID-19の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 抗生物質耐性市場情勢

  • 抗生物質耐性市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 抗生物質耐性市場 - 疾患タイプ別

  • 概要
    • 疾患タイプ別セグメントシェア分析
    • 尿路感染
    • 腹腔内感染症
    • 血流感染症
    • クロストリジウム・ディフィシル感染症
    • その他

第8章 抗生物質耐性市場 - 病原体タイプ別

  • 概要
    • 病原体タイプ別セグメントシェア分析
    • アシネトバクター・バウマニ
    • 緑膿菌
    • 黄色ブドウ球菌
    • 肺炎連鎖球菌
    • その他

第9章 抗生物質耐性市場 - 薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • オキサゾリジノン
    • リポ糖ペプチド
    • テトラサイクリン系
    • その他

第10章 抗生物質耐性市場 - エンドユーザー別

  • 概要
    • エンドユーザー別のセグメントシェア分析
    • 病院
    • ホームケア
    • 専門クリニック
    • その他

第11章 抗生物質耐性市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析 - 抗生物質耐性産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Achaogen Inc
    • Nabriva Therapeutics plc
    • BioVersys AG
    • Johnson &Johnson Services, Inc.
    • Destiny Pharma plc
    • Armata Pharmaceuticals, Inc.
    • West Way Health
    • The Medicines Company
    • Merck &Co., Inc.
    • Pfizer Inc.
    • CARB-X
    • Melinta Therapeutics LLC
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • GSK plc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd

第13章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Antibiotic Resistance Market: Disease Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Type
  • TABLE Global Antibiotic Resistance Market, by Disease Type 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: Pathogen Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Pathogen Type
  • TABLE Global Antibiotic Resistance Market, by Pathogen Type 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Antibiotic Resistance Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: End-User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Antibiotic Resistance Market, by End-User 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Antibiotic Resistance Market, by Region 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)

List of Figures

  • FIGURE Antibiotic Resistance Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Disease Type segment market share analysis, 2022 & 2030
  • FIGURE Disease Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Pathogen Type segment market share analysis, 2022 & 2030
  • FIGURE Pathogen Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE End-User segment market share analysis, 2022 & 2030
  • FIGURE End-User segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Antibiotic Resistance Market share and leading players, 2022
  • FIGURE Europe Antibiotic Resistance Market share and leading players, 2022
  • FIGURE Asia Pacific Antibiotic Resistance Market share and leading players, 2022
  • FIGURE Latin America Antibiotic Resistance Market share and leading players, 2022
  • FIGURE Middle East and Africa Antibiotic Resistance Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Antibiotic Resistance Market share analysis by country, 2022
  • FIGURE Germany Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Antibiotic Resistance Market share analysis by country, 2022
  • FIGURE India Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Antibiotic Resistance Market share analysis by country, 2022
  • FIGURE Brazil Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Antibiotic Resistance Market share analysis by country, 2022
  • FIGURE Saudi Arabia Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Antibiotic Resistance Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1722

REPORT HIGHLIGHT

Antibiotic Resistance Market size was valued at USD 8,005.7 million in 2022, expanding at a CAGR of 6.1% from 2023 to 2030.

Antibiotic resistance emerges when bacteria adapt to the usage of these medications. It develops in bacteria instead of people or animals. These bacteria can infect humans and animals, and their infections are more difficult to treat than infections caused by non-resistant bacteria. Antibiotic resistance is accelerated by antibiotic abuse and overuse, as well as inadequate infection prevention and control. At all levels of society, steps can be made to decrease the impact and spread of resistance. Antibiotic resistance is a global issue and requires cooperation between nations, industries, and organizations. Investing in the development of new antibiotics, as well as alternative therapies like bacteriophages and antimicrobial peptides. For example, Methicillin-Resistant Staphylococcus Aureus (MRSA's) emergence and spread show the quick rate at which germs can adapt to drugs, as well as the continual problem that healthcare personnel face in treating bacterial illnesses. It emphasizes the critical need for effective antibiotic usage, improved infection control procedures, and the discovery of novel antibiotics.

Antibiotic Resistance Market - Market Dynamics:

  • Increasing the prevalence of bacterial infection to increase market growth
  • The increasing prevalence of bacterial illnesses resistant to conventional antibiotics may increase demand for novel remedies, driving market growth. As antibiotic resistance spreads, the need for new antibiotics becomes more pressing. This could lead to increased investment in R&D by pharmaceutical corporations. Global comprehensive estimates of the burden of bacterial infections have been published. In 2019, 7.7 million deaths around the world were found to be linked to bacterial infections. That equals 1 in 8 of all global deaths. The integration of AI and machine learning in drug research provides a growth opportunity to accelerate the creation of novel antibiotics. However, Antibiotic resistance is not widely recognized by the general population and even by healthcare providers. This can lead to incorrect prescribing and abuse.

Antibiotic Resistance Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Antibiotic Resistance market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2023-2030)
  • Based on Disease type segmentation, Urinary Tract Infections was predicted to show maximum market share in the year 2022
  • Based on Pathogen Type segmentation, Acinetobacter Baumannii was the leading type in 2022
  • Based on Drug class segmentation, Oxazolidinones were the leading type in 2022
  • Based on End-User segmentation, Hospitals was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Antibiotic Resistance Market- Segmentation Analysis:

  • The Global Antibiotic Resistance Market is segmented on the basis of Disease type, Pathogen Type, Drug class, End-User, and Region.
  • The market is divided into four categories based on Disease type: Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, and Others. Urinary Tract Infections dominate the market growth. UTIs are one of the most common bacterial diseases that affect humans, particularly women. UTIs are often treated with antibiotics. However, with the increasing prevalence of antibiotic resistance, managing and treating UTIs is becoming more difficult.
  • The market is divided into four categories based on Pathogen Type: Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus pneumonia, and Others. Acinetobacter Baumannii dominates the market growth. A. baumannii has an inherent propensity to rapidly acquire resistance mechanisms, making it one of the most troublesome infections in hospital settings, particularly in intensive care units (ICUs).
  • The market is divided into three categories based on Drug class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others. The Oxazolidinones sector dominates the market and is likely to maintain its dominance during the forecast period. Oxazolidinones are antibiotics that are used to treat bacterial infections, particularly those caused by Gram-positive pathogens. Linezolid is the most well-known oxazolidinone. They are especially significant since they have been shown to be effective against multi-drug resistance pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
  • The market is divided into three categories based on End-User: Hospitals, Homecare, Specialty Clinics, and Others. The hospital sector dominates the market. Hospitals are essential to the development of antibiotic resistance. They are both a breeding ground for resistant bacteria and a main battleground for treating people sick with these superbugs. The implications for hospitals in the face of developing antibiotic resistance are complex, with considerable ramifications for the healthcare market.

Antibiotic Resistance Market - Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the market, due to the increasing prevalence of infectious diseases and rising healthcare expenditure. North America, especially the United States, has had outbreaks of many infectious diseases, some of which are antibiotic-resistant. MRSA (Methicillin-resistant Staphylococcus aureus), for example, has become a major concern in many U.S. hospitals and healthcare settings. The United States spends more on healthcare per capita than any other country in the world. According to the American Medical Association, a significant amount of the revenue is spent on research, drug development, and diagnostics. Health spending in the U.S. increased by 2.7% in 2021 to USD 4.3 trillion or USD 12,914 per capita. This growth rate is substantially lower than in 2020 (10.3% percent). Europe and Asia Pacific are projected to demand for Bispecific Resistance Market, due to the growing demand for effective antibiotic therapies.

Antibiotic Resistance Market- Competitive Landscape:

Antibiotic resistance has emerged as a major global concern. As bacteria evolve and become resistant to existing medicines, infections become more challenging to treat, leading to longer illnesses, more hospitalizations, and a rise in mortality. The manufacturers have been active in antibiotic research, however owing to economic pressures, some large pharmaceutical corporations have reduced or discontinued their antibiotic research projects. Pfizer, Merck, GlaxoSmithKline, and Roche represent some of the companies involved in the pharmaceutical industry. A comprehensive competitive study must consider pharmaceutical businesses, diagnostic companies, research institutes, and alternative treatment modalities. For instance, On May 2021, Basilea Pharmaceutical Ltd. (SIX: BSLN) announced today that it has been awarded a grant of up to USD 2.7 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global partnership dedicated to supporting the early development of antibacterial products to diagnose, prevent and treat drug-resistant infections.

Recent Developments:

November 18, 2020, Merck, known as MSD outside the United States and Canada, recently, announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world's largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIBIOTIC RESISTANCE MARKET KEY PLAYERS

  • Achaogen Inc
  • Nabriva Therapeutics plc
  • BioVersys AG
  • Johnson & Johnson Services, Inc.
  • Destiny Pharma plc
  • Armata Pharmaceuticals, Inc.
  • West Way Health
  • The Medicines Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • CARB-X
  • Melinta Therapeutics LLC
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • GSK plc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISEASE TYPE

  • Urinary Tract Infection
  • Intra-Abdominal Infections
  • Blood Stream Infections
  • Clostridium Difficile Infections
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY PATHOGEN TYPE

  • Acinetobacter Baumannii
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Streptococcus pneumoniae
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUG CLASS

  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END-USER

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antibiotic Resistance Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antibiotic Resistance Market Snippet by Disease Type
    • 2.1.2. Antibiotic Resistance Market Snippet by Pathogen Type
    • 2.1.3. Antibiotic Resistance Market Snippet by Drug Class
    • 2.1.4. Antibiotic Resistance Market Snippet by End-User
    • 2.1.5. Antibiotic Resistance Market Snippet by Country
    • 2.1.6. Antibiotic Resistance Market Snippet by Region
  • 2.2. Competitive Insights

3. Antibiotic Resistance Key Market Trends

  • 3.1. Antibiotic Resistance Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antibiotic Resistance Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antibiotic Resistance Market Opportunities
  • 3.4. Antibiotic Resistance Market Future Trends

4. Antibiotic Resistance Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antibiotic Resistance Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antibiotic Resistance Market Landscape

  • 6.1. Antibiotic Resistance Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antibiotic Resistance Market - By Disease Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Type, 2022 & 2030 (%)
    • 7.1.2. Urinary Tract Infection
    • 7.1.3. Intra-Abdominal Infections
    • 7.1.4. Blood Stream Infections
    • 7.1.5. Clostridium Difficile Infections
    • 7.1.6. Others

8. Antibiotic Resistance Market - By Pathogen Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Pathogen Type, 2022 & 2030 (%)
    • 8.1.2. Acinetobacter Baumannii
    • 8.1.3. Pseudomonas Aeruginosa
    • 8.1.4. Staphylococcus Aureus
    • 8.1.5. Streptococcus pneumoniae
    • 8.1.6. Others

9. Antibiotic Resistance Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 9.1.2. Oxazolidinones
    • 9.1.3. Lipoglycopeptides
    • 9.1.4. Tetracyclines
    • 9.1.5. Others

10. Antibiotic Resistance Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2022 & 2030 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Specialty Clinics
    • 10.1.5. Others

11. Antibiotic Resistance Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Antibiotic Resistance Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Antibiotic Resistance Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Antibiotic Resistance Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Antibiotic Resistance Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Antibiotic Resistance Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Antibiotic Resistance Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Achaogen Inc
    • 12.2.2. Nabriva Therapeutics plc
    • 12.2.3. BioVersys AG
    • 12.2.4. Johnson & Johnson Services, Inc.
    • 12.2.5. Destiny Pharma plc
    • 12.2.6. Armata Pharmaceuticals, Inc.
    • 12.2.7. West Way Health
    • 12.2.8. The Medicines Company
    • 12.2.9. Merck & Co., Inc.
    • 12.2.10. Pfizer Inc.
    • 12.2.11. CARB-X
    • 12.2.12. Melinta Therapeutics LLC
    • 12.2.13. Novartis AG
    • 12.2.14. Vertex Pharmaceuticals Incorporated
    • 12.2.15. GSK plc.
    • 12.2.16. AbbVie Inc.
    • 12.2.17. F. Hoffmann-La Roche Ltd

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us